143 related articles for article (PubMed ID: 17447854)
1. Isotype class switching after transplantation in multiple myeloma.
Maisnar V; Tichý M; Smolej L; Zák P; Radocha J; Palicka V; Malý J; Bláha V
Neoplasma; 2007; 54(3):225-8. PubMed ID: 17447854
[TBL] [Abstract][Full Text] [Related]
2. Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation.
Zent CS; Wilson CS; Tricot G; Jagannath S; Siegel D; Desikan KR; Munshi N; Bracy D; Barlogie B; Butch AW
Blood; 1998 May; 91(9):3518-23. PubMed ID: 9558413
[TBL] [Abstract][Full Text] [Related]
3. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
Kim JS; Kim K; Cheong JW; Min YH; Suh C; Kim H; Jo DY; Ryoo HM; Yoon SS; Lee JH;
Biol Blood Marrow Transplant; 2009 Apr; 15(4):463-70. PubMed ID: 19285634
[TBL] [Abstract][Full Text] [Related]
4. Abnormal protein bands in patients with multiple myeloma after haematopoietic stem cell transplantation: does it have a prognostic significance?
Sucak G; Suyanı E; Özkurt ZN; Yeğin ZA; Aki Z; Yagci M
Hematol Oncol; 2010 Dec; 28(4):180-4. PubMed ID: 20155734
[TBL] [Abstract][Full Text] [Related]
5. Outcome after autologous stem cell transplantation for multiple myeloma in patients with preceding plasma cell disorders.
Kumar SK; Dingli D; Lacy MQ; Dispenzieri A; Hayman SR; Buadi FK; Rajkumar SV; Litzow MR; Gertz MA
Br J Haematol; 2008 Apr; 141(2):205-11. PubMed ID: 18318761
[TBL] [Abstract][Full Text] [Related]
6. [Isotype switching of produced immunoglobulins in multiple myeloma].
Drobiecki A; Kisiel E; Wasińska E
Przegl Lek; 2003; 60(2):120-2. PubMed ID: 12939860
[TBL] [Abstract][Full Text] [Related]
7. Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation.
Ayuk F; Perez-Simon JA; Shimoni A; Sureda A; Zabelina T; Schwerdtfeger R; Martino R; Sayer HG; Alegre A; Lahuerta JJ; Atanackovic D; Wolschke C; Nagler A; Zander AR; San Miguel JF; Kröger N
Haematologica; 2008 Sep; 93(9):1343-50. PubMed ID: 18641030
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of the appearance of abnormal protein band in patients with multiple myeloma.
Jo JC; Yoon DH; Kim S; Lee K; Kang EH; Jang S; Park CJ; Chi HS; Huh J; Park CS; Suh C
Ann Hematol; 2014 Mar; 93(3):463-9. PubMed ID: 23999647
[TBL] [Abstract][Full Text] [Related]
9. Single-centre experience with nonmyeloablative allogeneic stem cell transplantation in patients with multiple myeloma: prolonged remissions induced.
van Dorp S; Meijer E; van de Donk NW; Dekker AW; Nieuwenhuis K; Minnema MC; Petersen E; Schutgens R; Verdonck LF; Lokhorst HM
Neth J Med; 2007 May; 65(5):178-84. PubMed ID: 17519513
[TBL] [Abstract][Full Text] [Related]
10. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
[TBL] [Abstract][Full Text] [Related]
11. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
[TBL] [Abstract][Full Text] [Related]
12. Higher infused lymphocyte dose predicts higher lymphocyte recovery, which in turn, predicts superior overall survival following autologous hematopoietic stem cell transplantation for multiple myeloma.
Hiwase DK; Hiwase S; Bailey M; Bollard G; Schwarer AP
Biol Blood Marrow Transplant; 2008 Jan; 14(1):116-24. PubMed ID: 18158968
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic stem cell transplantation in first complete remission enhances graft-versus-leukemia effect in adults with acute lymphoblastic leukemia: antileukemic activity of chronic graft-versus-host disease.
Lee S; Cho BS; Kim SY; Choi SM; Lee DG; Eom KS; Kim YJ; Kim HJ; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Shin WS; Kim CC
Biol Blood Marrow Transplant; 2007 Sep; 13(9):1083-94. PubMed ID: 17697971
[TBL] [Abstract][Full Text] [Related]
14. Immune Signatures Associated With Clonal Isotype Switch After Autologous Stem Cell Transplantation for Multiple Myeloma.
Ye R; Kundrapu S; Gerson SL; Driscoll JJ; Beck R; Ali N; Landgren O; VanHeeckeren W; Luo G; Kroger N; Caimi P; De Lima M; Malek E
Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):e213-e220. PubMed ID: 30878316
[TBL] [Abstract][Full Text] [Related]
15. Long-term outcome of autologous stem cell transplantation in light chain deposition disease.
Lorenz EC; Gertz MA; Fervenza FC; Dispenzieri A; Lacy MQ; Hayman SR; Gastineau DA; Leung N
Nephrol Dial Transplant; 2008 Jun; 23(6):2052-7. PubMed ID: 18178602
[TBL] [Abstract][Full Text] [Related]
16. Peripheral blood or bone marrow cells in reduced-intensity or myeloablative conditioning allogeneic HLA identical sibling donor transplantation for multiple myeloma.
Gahrton G; Iacobelli S; Bandini G; Björkstrand B; Corradini P; Crawley C; Hegenbart U; Morgan G; Kröger N; Schattenberg A; Schönland SO; Verdonck LF; Volin L; de Witte T; Niederwieser D;
Haematologica; 2007 Nov; 92(11):1513-8. PubMed ID: 18024400
[TBL] [Abstract][Full Text] [Related]
17. Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma.
de Lavallade H; El-Cheikh J; Faucher C; Fürst S; Stoppa AM; Coso D; Bouabdallah R; Chabannon C; Gastaut JA; Blaise D; Mohty M
Bone Marrow Transplant; 2008 Jun; 41(11):953-60. PubMed ID: 18297115
[TBL] [Abstract][Full Text] [Related]
18. [Prognostic factors affecting survival in multiple myeloma].
Tornóczky J; Tóth A; Sziládi E; Hoffmann E; Liszátz M
Orv Hetil; 1990 Aug; 131(31):1679-84. PubMed ID: 2205822
[TBL] [Abstract][Full Text] [Related]
19. Kinetics of paraprotein clearance after autografting for multiple myeloma.
Singhal S; Powles R; Milan S; Raje N; Viner C; Treleaven J; Raymond J; Cunningham D; Mehta J
Bone Marrow Transplant; 1995 Oct; 16(4):537-40. PubMed ID: 8528169
[TBL] [Abstract][Full Text] [Related]
20. Antigen-specificity of oligoclonal abnormal protein bands in multiple myeloma after allogeneic stem cell transplantation.
Rahlff J; Trusch M; Haag F; Bacher U; Horst A; Schlüter H; Binder M
Cancer Immunol Immunother; 2012 Oct; 61(10):1639-51. PubMed ID: 22350072
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
